肝细胞癌伴门静脉癌栓的介入综合治疗

朱晓黎

doi:10.3969/j.issn.1001-5256.2015.06.010

肝细胞癌伴门静脉癌栓的介入综合治疗

DOI: 10.3969/j.issn.1001-5256.2015.06.010

朱晓黎

苏州大学附属第一医院介入科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 3005
- HTML全文浏览量: 16
- PDF下载量: 576
- 被引次数: 0
出版历程
- 出版日期: 2015-06-20

Comprehensive interventional treatment of hepatocellular carcinoma with portal vein tumor thrombosis

Zhu XiaoLi

摘要

摘要: 伴门静脉癌栓(PVTT)的肝细胞癌(HCC)常见于进展期肝癌,PVTT可引起肿瘤播散、肝功能衰竭和门静脉高压,从而导致顽固性腹水、静脉曲张破裂和肝性脑病,严重影响肝癌患者预后。根据巴塞罗那临床肝癌分期(BCLC),伴PVTT的进展期HCC,索拉非尼被推荐为一线治疗方案,但由于其疗效有限且价格昂贵限制了它在国内的应用。而介入治疗以其微创、可重复性等优点在临床得到广泛应用,并取得一定的疗效。目前主要应用的介入治疗方法包括:经肝动脉灌注化疗术(HAIC)、经肝动脉化疗栓塞术(TACE)、TACE联合索拉非尼、TACE联合消融术、TACE联合适形放疗、TACE联合门静脉支架、门静脉粒子条置放术、经颈静脉肝内门体分流术(TIPS)等。最后指出多种方法综合治疗有望取得较好疗效。
- 癌,肝细胞 /
- 门静脉癌栓 /
- 综合疗法
Abstract: Portal vein tumor thrombosis( PVTT) often occurs in advanced hepatocellular carcinoma( HCC) patients. PVTT may cause tumor dissemination,liver failure,and portal hypertension,thus leading to intractable ascites,variceal rupture,and hepatic encephalopathy,which will result in a poor prognosis. According to the Barcelona Clinic Liver Cancer Staging System,sorafenib is recommended as the first- line treatment for advanced HCC with PVTT,but its application in China has been limited due to its mild efficacy and high price.Nowadays,interventional treatment is widely used in the treatment of advanced HCC with PVTT due to the advantages of minimal invasiveness and repeatability and shows good efficacy. At present,the main methods of interventional treatment include hepatic arterial infusion chemotherapy,transcatheter arterial chemoembolization( TACE),TACE combined with sorafenib,TACE combined with ablation,TACE combined with three- dimensional conformal radiotherapy,TACE combined with portal vein stent placement,endovascular implantation of iodine- 125 seeds strand,and transjugular intrahepatic portosystemic shunt. It is pointed out that multimodality treatment is expected to achieve good efficacy in the treatment of advanced HCC with PVTT.
- carcinoma,hepatocellular /
- portal vein tumor thrombosis /
- combined modality therapy

HTML全文

参考文献(56)

[1]VILLA E,MOLES A,FERRETTI I,et al.Natural history of inoperable hepatocellular carcinoma:estrogen receptors'status in the tumor is the strongest prognostic factor for survival[J].Hepatology,2000,32(2):233-238.

[2]TAWADA A,CHIBA T,OOKA Y,et al.Efficacy of transarterial chemoembolization targeting portal vein tumor thrombus in patients with hepatocellular carcinoma[J].Anticancer Res,2014,34(8):4231-4238.

[3]BRUIX J,SHERMAN M.Management of hepatocellular carcinoma:an update[J].Hepatology,2011,53(3):1020-1022.

[4]European Association for the Study of the Liver,European Organisation for Research and Treatment of Cancer.EASL-EORTC clinical practice guidelines:management of hepatocellular carcinoma[J].J Hepatol,2012,56(4):908-943.

[5]OMATA M,LESMANA LA,TATEISHI R,et al.Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma[J].Hepatol Int,2010,4(2):439-474.

[6]CHENG AL,KANG YK,CHEN Z,et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phase III randomised,double-blind,placebo-controlled trial[J].Lancet Oncol,2009,10(1):25-34.

[7] LLOVET JM,RICCI S,MAZZAFERRO V,et al.Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med,2008,359(4):378-390.

[8]SONGA ZZ,HUANG M,JIANGTA,et al.Diagnosis of portal vein thrombosis discontinued with liver tumors in patients with liver cirrhosis and tumors by contrast-enhanced US:a pilot study[J].Eur J Radio,2010,75(2):185-188.

[9] LUO J,GUO RP,LAI EC,et al.Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis:a prospective comparative study[J].Ann Surg Oncol,2011,18(2):413-420.

[10]LAU WY,SANGRO B,CHEN PJ,et al.Treatment for hepatocellular carcinoma with portal vein tumor thrombosis:the emerging role for radioembolization using yttrium-90[J].Oncology,2013,84(5):311-318.

[11] ZHU K,CHEN J,LAI L,et al.Hepatocellular carcinoma with portal vein tumor thrombus:treatment with transarterial chemoembolization combined with sorafenib-a retrospective controlled study[J].Radiology,2014,272(1):284-293.

[12]KUDO M,IZUMI N,KOKUDO N,et al.Management of hepatocellular carcinoma in Japan:consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology(JSH)2010 updated version[J].Dig Dis,2011,29(3):339-364.

[13]SHI J,LAI E,LI N,et al.Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus[J].Ann Surg Oncol,2010,17(8):2073-2080.

[14] SHI J,LAI E,LI N,et al.A new classification for hepatocellular carcinoma with portal vein tumor thrombus[J].J Hepatobiliary Pancreat Sci,2011,18(1):74-80.

[15]EDGE SB,BYRD DR,COMPTON CC,et al.AJCC cancer staging manual[M].7th ed.New York:Springer,2010:191-200.

[16]GRAF D,VALLBHMER D,KNOEFEL WT,et al.Multimodal treatment of hepatocellular carcinoma[J].Eur JIntern Med,2014,25:430-437.

[17]Ministry of Health of the Peoples Republic of China.Diagnosis,management and treatment of hepatocellular carcinoma(2011 version)[J].J Clin Hepatol,2011,27(11):1141-1159.(in Chinese)中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)[J].临床肝胆病杂志,2011,27(11):1141-1159.

[18]SCHWARZ RE,ABOU-ALFA GK,GESCHWIND JF,et al.Nonoperative therapies for combined modality treatment of hepatocellular cancer:expert consensus statement[J].HPB(Oxford),2010,12(5):313-320.

[19]PAUL SB,SHARMA H.Role of transcatheter intra-arterial therapies for hepatocellular carcinoma[J].J Clin Expheatol,2014,4(Suppl 3):s112-s121.

[20]BAEK YH,KIM KT,LEE SW,et al.Efficacy of hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma[J].World J Gastroenterol,2012,18(26):3426-3434.

[21]IKEDA M,OKUSAKA T,FURUSE J,et al.A multi-institutional phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis[J].Cancer Chemother Pharmacol,2013,72(2):463-470.

[22]KASAI K,USHIO A,KASAI Y,et al.Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon a-2b for advanced hepatocellular carcinoma with portal venous invasion[J].Cancer,2012,118:3302-3310.

[23]SON DS,BAE SH,SONG MJ,et al.Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosisa[J].World J Gastroenterol,2013,19(29):4679-4688.

[24]CHUNG YH,SONG H,SONG CB,et al.Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-a for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis[J].Cancer,2000,88:1986-1991.

[25]NAGANO H,KOBAYASHI S,MARUBASHI S,et al.Combined IFN-αand 5-FU treatment as a postoperative adjuvant following surgery for hepatocellular carcinoma with portal venous tumor thrombu[J].Exp Ther Med,2013,5(1):3-10.

[26] European Association For the Study of Liver,European Organisation for Research and Treatment of Cancer.EASL-EORTC clinical practice guidelines:management of hepatocellular carcinoma[J].J Hepatol,2012,56(4):908-943.

[27]NIU ZJ,MA YL,KANG P,et al.Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus:using a new classification[J].Med Oncol,2012,29(4):2992-2997.

[28]LUO J,GUO RP,LAI ECH,et al.Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis:a prospective comparative study[J].Ann Surg Oncol,2011,18(2):413-420.

[29]YE JZ,ZHANG YQ,YE HH,et al.Appropriate treatment strategies improve survival of hepatocellular carcinoma patients with portal vein tumor thrombus[J].World J Gastroenterol,2014,20(45):17141-17147.

[30]ZHOU Q,WANG Y,ZHOU X,et al.Prognostic analysis for treatment modalities in hepatocellular carcinomas with portal vein tumor thrombi[J].Asian Pac J Cancer Prev,2011,12(11):2847-2850.

[31]CHUNG GE,LEE JH,KIM HY.Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival[J].Radiology,2011,258(2):627-634.

[32]LENG JJ,XU YZ,DONG JH.Efficacy of transarterial chemoembolization for hepatocellular carcinoma with portal vein thrombosis:a meta-analysis[J].ANZ J Surg,2014.[Epub ahead of print]

[33]ZHAO Y,CAI GH,ZHOU L,et al.Transarterial chemoembolization in hepatocellular carcinoma with vascular invasion or extrahepatic metastasis:a systematic review[J].Asia Pac J Clin Onco,2013,9(4):357-364.

[34]NOVI M,LAURITANO EC,PISCAGLIA AC,et al.Portal vein tumor thrombasis revascularization during sorafenib treatment for hepatocellular carcinorna[J].Arn J Gastroenterol,2009,104(7):1852-1854.

[35]QU XD,CHEN CS,WANG JH,et al.The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma[J].BMC Cancer,2012,12:263.

[36]ZHU K,CHEN J,LAI L,et al.Hepatocellular carcinoma with portal vein tumor thrombus:treatment with transarterial chemoembolization combined with sorafenib-a retrospective controlled study[J].Radiology,2014,272(1):284-293.

[37]BAI W,WANG YJ,ZHAO Y,et al.Sorafenib in combination with transarterial chemoembolization improves survival of unresectablehepatocellular carcinoma:a propensity score matching study[J].J Dig Dis,2013,14(4):181-190.

[38]TAN WF,QIU ZQ,YU Y,et al.Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation[J].Acta Pharmacol Sin,2010,31(12):1643-1648.

[39] CHEN JW,PANG PF,MENG XC,et al.Clinical observation of transcatheter arterial chemoembolization plus sorafenib in the treatment of advanced hepatocellular carcinoma with different types of portal vein tumor thrombosis[J].Natl Med J China,2013,93(9):663-667.(in Chinese)陈俊伟,庞鹏飞,孟晓春,等.TACE联合索拉非尼治疗原发性肝癌合并同分型门静脉癌栓的临床观察[J].中华医学杂志,2013,93(9):663-667.

[40]PAN T,LI XS,XIE QK,et al.Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus[J].Clin Radiol,2014,69(12):553-561.

[41]PARK JW,KOH YH,KIM HB,et al.Phase II study of concurrent transarterial chemoembolization and sorafenib for patients with unresectable hepatocellular carcinoma[J].J Hepatol,2012,56(6):1336-1342.

[42]CHAOY,CHUNG YH,HAN GH,et al.The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma:final results of the START trial[J].Int J Cancer,2015,136(6):1458-1467.

[43]ZHENG JS,LONG J,SUN B,et al.Transcatheter arterial chemoembolization combined with radiofrequency ablation can improve survival of patients with hepatocellular carcinoma with portal vein tumour thrombosis:Extending the indication for ablation?[J].Clin Radiol,2014,69(6):e253-e263.

[44]BECKER G,SOEZGEN T,OLSCHEWSKI M,et al.Combined TACE and PET for palliative treatment of unresectable hepatocellular carcinoma[J].World J Gastoentero,2005,11(39):6104-6109.

[45]LI C,ZHANG W,ZHANG R,et al.Therapeutic effects and prognostic factors in high—intensity focused ultrasound combined with chemoembolisation for larger hepatocellular carcinoma[J].Eur J Cancer,2010,46(13):2513-2521.

[46]ARIENTI V,PRETOLANI S,PACELLA CM,et al.Complications of laser ablation for hepatocellular carcinoma:a multicenter study[J].Radiology,2008,246(3):947-955.

[47]LIANG LJ,HU WJ,YIN XY,et al.Adjuvant intraportal venous chemotherapy for patients with hepatocellular carcinoma and portal vein tumor thrombi following hepatectomy plus portal thrombectomy[J].World J Surg,2008,32(4):627-631.

[48]CHUAN-XING L,XU H,BAO-SHAN H,et al.Efficacy of therapy for hepatocellular carcinoma with portal vein tumor thrombus Chemoembolization and stent combined with iodine-125 seed[J].Cancer Biol Ther,2011,12(10):865-871.

[49]ZHANG L,LU LG,LI Y,et al.Portal vein stent placement combined with TACE for the treatment of hepatocellular carcinoma associated with tumor thrombus in portal vein[J].J Intervent Radiol,2011,20(12):968-973.(in Chinese)张磊,陆骊工,李勇,等.门静脉支架联合肝动脉化疗栓塞治疗肝癌伴门静脉癌栓的临床研究[J].介入放射学杂志,2011,20(12):968-973.

[50]YOON SM,LIM YS,WON HJ,et al.Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the potal vein:long-term putcomes[J].Int J Radiat Oncol Biol Phys,2012,82(5):2004-2011.

[51]FUJINO H,KIMURA T,AIKATA H,et al.Role of 3-D conformal radiotherapy for major portal vein tumor thrombosis combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma[J].Hepatol Res,2014.[Epub ahead of print]

[52]TANG QH,LI AJ,YANG GM,et al.Surgical resection versus conformal radiotherapy combined with tace for resectable hepatocellular carcinoma with portal vein tumor thrombus:a comparative study[J].World J Surg,2013,37(6):1362-1370.

[53]PRACHT M,EDELINE J,LENOIR L,et al.Lobar hepatocellular carcinoma with ipsilateral portal vein tumor thrombosis treated with yttrium-90 glass microsphere radioembolization:preliminary results[J].Int J Hepatol,2013,2013:827649.

[54]IKAI I,HATANO E,HASEGAWA S,et al.Prognostic index for patients with hepatocellular carcinoma combined with tumor thrombosis in the major portal vein[J].J Am Coll Surg,2006,202(3):431-438.

[55]JIA L,KIRYU S,WATADANI T,et al.Prognosis of hepatocellular carcinoma with portal vein tumor thrombus:assessment based on clinical and computer tomography characteristics[J].Acat Med Okayma,2012,66(2):131-141.

[56]CHEN JS,WANG Q,CHEN XL,et al.Clinicopathologic characteristics and surgical outcomes of hepatocellular carcinoma with portal vein tumor thrombosis[J].J Surg Res,2012,175(2):243-250.

施引文献

资源附件(0)

访问统计